In a shocking reversal of the progress made by the medical freedom movement, Attorney General Jeff Sessions has decided to undo the right of individual states to set marijuana laws and instead will be subject to the dictates of the federal government.
But even worse, Sessions proved both his hypocrisy and corruption when his own DEA granted notorious pharmaceutical company Insys Therapeutics a virtual monopoly to make profits off of synthetic THC.
Jeff Sessions should focus on how Congress crippled the DEA’s ability to fight the opioid epidemic. Instead he tramples upon states’ rights and recreational marijuana laws.
64,000 Americans died last year from opioids. None have died from THC. But, you know, priorities.
— Eugene Gu, MD (@eugenegu) January 4, 2018
A statement released on Thursday by the Department of Justice unveiled the new tyrannical philosophy:
“It is the mission of the Department of Justice to enforce the laws of the United States, and the previous issuance of guidance undermines the rule of law and the ability of our local, state, tribal, and federal law enforcement partners to carry out this mission.
“Therefore, today’s memo on federal marijuana enforcement simply directs all U.S. Attorneys to use previously established prosecutorial principles that provide them all the necessary tools to disrupt criminal organizations, tackle the growing drug crisis, and thwart violent crime across our country.”
But in a shocking (though unsurprising) display of pay-to-play, Session’s very own DEA—while classifying cannabis as a Schedule 1 drug—decided to classify the synthetic THC drug Dronabinol, produced by pharmaceutical company Insys Therapeutics, as Schedule 2.
Effectively, this gives Insys a monopoly over the “free market” of medical THC, a move that likely amounts to far more than just coincidence when you consider the company’s long history of illegal activity.
2017 Opioid overdose deaths (est): 70,000+
2017 Marijuana/THC overdose deaths (est): 0
Sessions & GOP:
Give hundreds of millions of federal tax breaks to pharmaceutical companies
Devote millions in federal prosecutorial spending to jailing potheads
— feminist next door (@emrazz) January 5, 2018
As The Free Thought Project reports:
“For those who don’t know, Insys has become notorious over the last two years after six former executives and managers were arrested on charges that they engaged in a nationwide scheme to bribe doctors to prescribe a drug containing the opioid fentanyl.
“Now this same group of dangerous drug peddlers is being given a partial national monopoly on the sale of legal THC, by the group who claims to protect Americans from drugs.
“Along with the executives, Michael Baich, the former CEO, was also charged in an indictment filed in federal court.
“Even the company’s billionaire founder, John Kapoor was arrested in October for his role in the bribery scheme. He was freed on a $1 million bail after pleading not guilty.”
Needless to say, the level of corruption at play here cannot be overstated, yet it’s nothing new for the medical freedom movement which has fought tirelessly for years on this matter, and many others.
President Trump has consistently referenced the opioid epidemic sweeping the country, which seems like it should be a much higher priority than cracking down on a harmless plant.
Indeed, back in October 2017, the President officially declared the opioid crisis a “national public health emergency”:
— Donald J. Trump (@realDonaldTrump) October 26, 2017